Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation

Leona Dold; Philipp Lutz; Annkristin Heine; Tobias Weismüller; Christian Strassburg; Ulrich Spengler

doi:10.22541/au.162050317.70513553/v1

loading page

Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation

Leona Dold,
Philipp Lutz,
Annkristin Heine,
Tobias Weismüller,
Christian Strassburg,
Ulrich Spengler

Abstract

Patients after liver transplantation have an increased risk to develop haematologic neoplasias. Information how to treat these patients in the context of immunosuppression is sparse. Here, we report two patients with polycythemia vera (PV) and myelofibrosis (MF) on ruxolitinib after liver transplantation.

19 Jan 2021Submitted to Clinical Case Reports

Show details

Hide details

21 Jan 2021Submission Checks Completed

21 Jan 2021Assigned to Editor

08 May 2021Reviewer(s) Assigned

22 May 2021Review(s) Completed, Editorial Evaluation Pending

24 May 2021Editorial Decision: Revise Minor

31 Jul 20211st Revision Received

31 Jul 2021Submission Checks Completed

31 Jul 2021Assigned to Editor

31 Jul 2021Review(s) Completed, Editorial Evaluation Pending

31 Jul 2021Reviewer(s) Assigned

15 Aug 2021Editorial Decision: Accept

Abstract

Peer review status:ACCEPTED